Report Date: Thursday, July 30, 2026, before market open | Call at 8:30 AM ET
REGN heads into tomorrow's report trading around $695–700, having clawed back roughly 11-12% off its late-May/June lows near $595-630, but still well below the ~$750-770 levels it traded at before Q1 earnings in late April. It's been a turbulent year: shares fell after the April 29 Q1 report itself, and then dropped sharply again on May 18 after a pivotal Phase 3 melanoma readout disappointed — a one-two punch that has defined the stock's 2026 narrative and set a cautious tone into this print.
Consensus expectations: Analysts are modeling revenue of roughly $3.8–3.84 billion (up only ~4-5% y/y, a marked deceleration from Q1's 19% growth) and non-GAAP EPS around $10.00–10.26, which would represent a ~20% year-over-year decline from Q2 2025's $12.89. Consensus revenue of $3.82 billion implies growth of just 3.8% compared to the $3.68 billion reported in Q2 2025, and the $10.26 per share estimate would mark a 20.4% drop from the year-ago result of $12.89. Notably, the current EPS consensus has declined 5.4% over the past 30 days and is down 3.4% from 90 days ago, reflecting souring sentiment. GAAP EPS estimates are lower still (~$8), given a pre-announced charge (see below).
Importantly, Regeneron has already told investors what to expect on one line item: the company expects to record a pretax acquired in-process R&D charge of about $127 million in Q2 2026, tied to upfront and opt-in payments under new collaboration and licensing agreements, projected to cut GAAP and non-GAAP EPS by roughly $1.00 for the quarter. The market largely shrugged this off — shares actually rose on the news, as investors appeared to look through the charge because it was tied to collaboration and licensing activity rather than a deterioration in the core business.
The single biggest event of the quarter was the May 15/18 disclosure that Regeneron's closely-watched Phase 3 trial of fianlimab (LAG-3 antibody) plus Libtayo in first-line metastatic melanoma failed to hit its primary endpoint. The trial did not achieve statistical significance for the primary endpoint of improvement in progression-free survival, though a numeric improvement of 5.1 months in median PFS was observed for the high-dose combination versus pembrolizumab monotherapy. The stock fell nearly 12% the following Monday, becoming the worst-performing stock in the S&P 500 that day, and triggered a wave of analyst downgrades — Citi moved to Neutral, cutting its target from $900 to $700, while Leerink downgraded to Market Perform, citing concerns about long-term EPS growth, potential Eylea underperformance, and biosimilar competition. The setback has also drawn securities class-action litigation alleging Regeneron misled investors about trial risk ahead of the readout — an overhang investors will want management to address. On the positive side, a separate Phase 3 head-to-head trial of the high-dose combination versus Bristol Myers' Opdualag is still ongoing, offering one more shot on goal, though sentiment on that readout is mixed.
The PFS regulatory saga continues to be an unresolved catalyst. As of the Q1 update, Regeneron had resubmitted its application for filling of the EYLEA HD PFS at Catalent Indiana following an FDA re-inspection, while the FDA had not acted by the April 2026 PDUFA date on a second contract manufacturer application, leaving that pending too. Management said on the Q1 call it had already received a CRL in October 2025 for this application, and there is no assurance FDA approval will come in the currently anticipated timeframe or at all. A decision (or further delay) here remains a key swing factor for the Eylea franchise's competitive positioning against Vabysmo and biosimilars.
Q1 GAAP gross margin was pressured by a temporary interruption of bulk manufacturing production at the company's Limerick, Ireland facility due to unanticipated repairs[ref to earnings release]. Management guided that GAAP gross margin would continue to be negatively impacted in Q2 as production returns to normal levels, with full-year GAAP gross margin guidance cut to 77–78% from 79–80%. Investors should watch whether Limerick is fully back online and whether margin guidance needs further adjustment.
Dupixent — still the growth engine. Q1 global Dupixent sales grew 33% to $4.9 billion, and the franchise keeps adding indications (pediatric CSU, allergic fungal rhinosinusitis, bullous pemphigoid in Japan). Watch commentary on next-gen pipeline defense given AbbVie's $10.9 billion acquisition of Apogee Therapeutics (announced June 22), whose lead asset zumilokibart is a far-less-frequent-dosing IL-13 antibody that could offer a meaningful convenience advantage over Dupixent. This is now a headline long-term competitive threat analysts will press management on.
Sanofi collaboration revenue step-up. Management flagged on the Q1 call that the Sanofi development balance was expected to be fully repaid by the end of Q2 2026, after which Sanofi collaboration revenue would step up to reflect Regeneron's full share of collaboration profits starting in Q3 — a structural tailwind investors should confirm is on track.
EYLEA/EYLEA HD trends. Watch for the pace of EYLEA HD sequential unit demand growth (management guided to ~10% sequential growth consistent with Q1) versus continued EYLEA erosion (guided mid-to-high-teens sequential demand decline) ahead of additional Eylea 2mg biosimilar launches expected in 2H26.
Libtayo momentum — continuing to scale post adjuvant CSCC launch; a bright spot with 54% global growth in Q1.
Pipeline catalysts to track for 2H26/2027 guidance: - Cemdisiran in generalized myasthenia gravis — FDA/EMA accepted filings with a target action date in November 2026 (Priority Review). - Cemdisiran+pozelimab PNH registrational data expected late Q4 2026. - Geographic atrophy interim C5 data expected Q4 2026. - Garetosmab (FOP) BLA — PDUFA date in August 2026, just after this earnings call. - Fianlimab adjuvant melanoma second interim/final analysis expected 2H26 — a chance to partially redeem the LAG-3 franchise. - Olatorepatide (GLP-1/GIP) obesity Phase 3 program initiation.
Capital allocation. Regeneron has a fresh $3 billion buyback authorization (on top of $688 million remaining from the prior program) and repurchased $803 million of stock in Q1 alone — watch buyback pace given the depressed share price, plus the quarterly dividend ($0.94/share).
Wall Street remains split. Recent price-target moves have been mixed but skew constructive on a medium-term view even after cuts: BofA's Tazeen Ahmad recently lowered her target to $856 from $860 while keeping a Buy, citing steady Eylea HD demand growth, while Guggenheim's Yatin Suneja raised his target to $1,000 from $995, keeping a Buy. On the more cautious side, Morgan Stanley's Terence Flynn cut his target to $730 from $788 (Equal Weight) and RBC Capital has repeatedly trimmed its target, most recently to $696 (Sector Perform). The dispersion in EPS estimates itself is unusually wide — from $7.64 to $12.33 across 22 analysts — underscoring genuine uncertainty about margin trajectory this quarter.
Bulls point to Regeneron as a strong buy after the pullback, arguing fianlimab was not critical for long-term value creation and that returning growth, an expanding pipeline, and a strong balance sheet position the company well. Bears counter that "back-to-back key pipeline misses amp up the pressure on the next 12 to 18 months of clinical development," as one BMO analyst put it after the melanoma miss, and note ongoing competitive pressure on Eylea HD (50% of US retina sales), biosimilar entry in 2H26, and continued PFS regulatory uncertainty.
This is a "show me" quarter. The headline financials should look soft on a GAAP basis (partly due to the pre-flagged $1.00/share IPR&D charge) and decelerating on revenue growth versus Q1's blowout comp, but the more important storylines are qualitative: (1) confirmation that Limerick manufacturing and gross margins are normalizing as guided; (2) clarity — or continued lack thereof — on the EYLEA HD pre-filled syringe decision; (3) management's framing of the pipeline post-fianlimab, including how they're addressing the securities litigation overhang and setting up expectations for upcoming cemdisiran, garetosmab, and GA readouts; and (4) any incremental color on defending Dupixent's franchise against the emerging Apogee/AbbVie long-acting IL-13 threat. Guidance commentary for the back half of 2026 — margins, R&D spend trajectory, and Sanofi collaboration economics — will likely matter more to the stock than the Q2 numbers themselves.